CLARITIN HIVES RELIEF REDITAB
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLARITIN HIVES RELIEF REDITAB (CLARITIN HIVES RELIEF REDITAB).
Selective inverse agonist of peripheral histamine H1 receptors, inhibiting histamine release from mast cells and basophils.
| Metabolism | Primarily metabolized by CYP3A4 to descarboethoxyloratadine; also metabolized by CYP2D6 to a lesser extent. |
| Excretion | Primarily renal (approximately 40% as metabolites, <1% as unchanged drug) and fecal (approximately 40% as metabolites). |
| Half-life | Terminal elimination half-life of loratadine is 8.4 hours (range 3–20 hours); for its active metabolite descarboethoxyloratadine, it is 24.9 hours (range 8.8–45 hours). Clinical context: Steady-state concentrations are achieved by day 5. |
| Protein binding | Loratadine: 97–99% bound to albumin and alpha-1-acid glycoprotein. Descarboethoxyloratadine: 73–76% bound. |
| Volume of Distribution | Loratadine: approximately 120 L/kg (high, indicating extensive tissue distribution). Descarboethoxyloratadine: 704 L/kg. |
| Bioavailability | Oral bioavailability of loratadine is 40–50% due to first-pass metabolism. The orally disintegrating tablet is bioequivalent to conventional tablets. |
| Onset of Action | Orally disintegrating tablet: Onset of antihistaminic effect within 1–3 hours. |
| Duration of Action | Duration of action: 24 hours for the active metabolite; clinical effect supports once-daily dosing. |
| Molecular Weight | 382.88 |
10 mg orally once daily
| Dosage form | TABLET, ORALLY DISINTEGRATING |
| Renal impairment | No adjustment required. CrCl 10-50 mL/min: use with caution; CrCl <10 mL/min: contraindicated if anuria. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B or C: start 5 mg orally once daily. |
| Pediatric use | 6-12 years: 5 mg orally once daily; >12 years: 10 mg orally once daily. Weight-based: not typically required. |
| Geriatric use | No specific adjustment; monitor for dizziness or sedation. |
| 1st trimester | Avoid use; limited human data but animal studies show no teratogenicity at clinically relevant doses. However, first trimester is critical for organogenesis. |
| 2nd trimester | Use only if clearly needed; no evidence of fetal harm in animal studies, but human data insufficient. |
| 3rd trimester | Use only if clearly needed; no specific concerns in late pregnancy, but avoid in third trimester unless benefit outweighs risk due to potential maternal hypotension. |
Clinical note
Comprehensive clinical and safety monograph for CLARITIN HIVES RELIEF REDITAB (CLARITIN HIVES RELIEF REDITAB).
| Placental transfer | Loratadine crosses the human placenta; cord blood concentration is about 5% of maternal serum concentration. Animal studies indicate placental transfer is limited. |
| Breastfeeding | Loratadine and its metabolite pass into breast milk in low amounts; average concentration is about 1.1 ng/mL, resulting in a relative infant dose of approximately 1.1% of the maternal weight-adjusted dose. No adverse effects observed in infants; consider monitoring for sedation or irritability. Compatible with breastfeeding. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to loratadine or any component of the formulation
| Precautions | Severe hepatic impairment (dose adjustment required); renal impairment (CrCl <30 mL/min, starting dose of 10 mg every other day); use with caution in patients with history of seizures; may impair ability to drive or operate machinery. |
| Food/Dietary | No significant food interactions. Grapefruit juice may slightly increase absorption but is clinically irrelevant. Avoid alcohol to minimize sedation risk. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects; no adequate human studies in pregnant women. Potential for minor malformations not established. Risk to fetus considered low based on limited data. |
| Fetal Monitoring | No specific fetal monitoring required. Observe for maternal allergic symptoms and response to therapy. Standard prenatal care. |
| Fertility Effects | No known adverse effects on fertility in animal or human studies. Loratadine does not impair male or female reproductive function at therapeutic doses. |
| Loratadine is a long-acting non-sedating antihistamine for chronic urticaria and allergic rhinitis. Onset within 1-3 hours, duration 24 hours. Avoid in severe hepatic impairment (Child-Pugh >10). No QT prolongation at therapeutic doses. |
| Patient Advice | Take once daily with or without food. · Do not exceed 1 tablet daily. · May cause drowsiness in rare cases; avoid driving if affected. · Not for immediate relief of hives; takes up to 3 hours for effect. · Stop use and consult doctor if hives persist >6 weeks or worsen. |